Annexon, Inc.

74 articles about Annexon, Inc.

• Annexon Announces Closing of Initial Public Offering

  7/28/2020

  Annexon, Inc. (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of its initial public offering of 14,750,000 shares of its common stock at a public offering price of $17.00 per share.

• Annexon Announces Pricing of Initial Public Offering - July 24, 2020

  7/24/2020

  Annexon, Inc. announced the pricing of its initial public offering of 14,750,000 shares of its common stock at a public offering price of $17.00 per share.

• 

  Annexon Raises $100 Million to Advance Therapies for Neurodegenerative, Autoimmune Disorders

  7/2/2020

  Annexon, based in South San Francisco, closed on a $100 million Series C financing led by Redmile Group.

• Annexon Closes $100 Million Financing to Advance Broad Pipeline of Classical Complement Therapeutics

  7/1/2020

  Annexon, Inc., a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain and eye, today announced the closing of a $100 million financing led by new investor Redmile Group.

•  Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX007 in Glaucoma

  10/9/2019

  Intravitreal ANX007 was well-tolerated and demonstrated full target engagement and inhibition of C1q in the eye for at least four weeks

• Annexon Biosciences Reports Top-line Phase 1b Results for Novel C1q Inhibitor ANX005 in Guillain-Barré Syndrome

  9/30/2019

  Annexon Biosciences announced encouraging results from a Phase 1b dose-ranging clinical trial to evaluate its anti-C1q antibody, ANX005.

• Annexon Biosciences Announces FDA Fast Track Designation for Novel C1q Inhibitor ANX005 for the Treatment of Guillain-Barré Syndrome

  9/23/2019

  Annexon plans to advance the clinical development of ANX005 for the treatment of GBS

• 

  BioSpace Movers and Shakers, July 12

  7/12/2019

  Biotech and pharma companies strengthen their leadership teams with new appointments.

• Annexon Biosciences Expands Senior Leadership as it Advances its Novel Complement Approach to Autoimmune and Neurodegenerative Disorders

  7/9/2019

  Sanjay Keswani, MBBS, BSc, FRCP, Chief Medical Officer Jennifer Lew, Chief Financial Officer Lesley Stolz, PhD, Chief Business Officer

• 

  Companies Note Collaborations, Financing and Clinical Trial Success

  12/26/2018

  With the holiday upon us, many companies in the pharma and biotech industry have made some important announcements – some big, some small. BioSpace has gathered a number of announcements that might have gone unnoticed and put them together below.

• Annexon Biosciences Closes $75 Million Financing

  12/19/2018

  Annexon Biosciences, a clinical stage biopharmaceutical company focused on the development of novel therapeutics through inhibition of the classical complement pathway, today announced that it has closed a $75 million Series C financing.

• Bioasis Further Strengthens Scientific Advisory Board with Addition of Dr. Mario Saltarelli, Dr. Jack Hoppin and Dr. Sue O’Connor

  6/12/2018

  BIOASIS TECHNOLOGIES INC. today announced the addition of Mario Saltarelli, M.D., Ph.D., Jack Hoppin, Ph.D. and Sue O’Connor, B.Sc. (Hons), Ph.D. to its scientific advisory board.

• Annexon Appoints Bill Young As Chairman And Adds Tom Wiggans To Board Of Directors

  3/9/2017

• Bay Area Startup Annexon Banks $44 Million Series B

  6/23/2016